Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late?

doi:10.4240/wjgs.v12.i4.149

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 4

This Article

(300)

(321)

(0)

(11)

(2)

(6008)

(11)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Retrospective Cohort Study

World J Gastrointest Surg. Apr 27, 2020; 12(4): 149-158
Published online Apr 27, 2020. doi: 10.4240/wjgs.v12.i4.149

Full Size Figure Download Figure

Figure 3 Survival of patients stratified by mammalian target of rapamycin inhibitor monotherapy vs combination therapy with calcineurin inhibitor (P = 0. 59). mTOR: Mammalian target of rapamycin.

Citation: Au KP, Chok KSH. Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late? World J Gastrointest Surg 2020; 12(4): 149-158
URL: https://www.wjgnet.com/1948-9366/full/v12/i4/149.htm
DOI: https://dx.doi.org/10.4240/wjgs.v12.i4.149

Au KP, Chok KSH. Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late? World J Gastrointest Surg 2020; 12(4): 149-158 [PMID: 32426094 DOI: 10.4240/wjgs.v12.i4.149]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.